Recombinant Human PTH, Fc-tagged-蛋白质/抗原/多肽-试剂-生物在线
北京安必奇生物科技有限公司
Recombinant Human PTH, Fc-tagged

Recombinant Human PTH, Fc-tagged

商家询价

产品名称: Recombinant Human PTH, Fc-tagged

英文名称: Recombinant Human PTH, Fc-tagged

产品编号: PTH-8562H

产品价格: 0

产品产地: USA

品牌商标: Creative Biomart

更新时间: null

使用范围: null

北京安必奇生物科技有限公司
  • 联系人 : 章先生
  • 地址 : 北京市通州区经海五路1号院22号楼
  • 邮编 :
  • 所在区域 : 北京
  • 电话 : 158****7462 点击查看
  • 传真 : 点击查看
  • 邮箱 : info@abace-biology.com

 http://www.creativebiomart.net/description_382703_12.htm

Parathyroid hormone (PTH), parathormone or parathyrin, is secreted by the chief cells of the parathyroid glands as a polypeptide. PTH elevates calcium level by dissolving the salts in bone and preventing their renal excretion. PTH may stimulates [1-14C]-2-deoxy-D-glucose (2DG) transport and glycogen synthesis in osteoblastic cells. Parathyroid hormone (PTH) has been proved to play a pivotal role in maintaining myocardial contractility as well as effective natriuresis, and possible pathogenic mechanisms contributing to heart failure secondary to hypocalcemia and hypoparathyroidism. With the increased population of preosteoblastic lineages and the osteoblastic activation, Parathyroid hormone (PTH) drives anabolism in bone. Experiments have recently reported that the absence of osteoclasts in c-fos(- / -) mice might hinder PTH-driven bone anabolism, and that osteoclastic presence may be necessary for full osteoblastic differentiation and enhanced bone formation seen after intermittent PTH administration. Alternatively, it was suggested that PTH administration inhibits sclerostin synthesis by osteocytes, thereby allowing for active bone formation. Taken together, Parathyroid hormone (PTH) affects bone cells in a dual pathway-mediating osteoblastic (preosteoblastic) activities or osteocytic synthesis of sclerostin. Defects in PTH are a cause of familial isolated hypoparathyroidism (FIH), also called autosomal dominant hypoparathyroidism or autosomal dominant hypocalcemia. FIH is characterized by hypocalcemia and hyperphosphatemia due to inadequate secretion of parathyroid hormone.